ANGIODYNAMICS, INC.

AngioDynamics launches RECOVER-AV trial to evaluate AlphaVac F18⁸⁵ System for acute, intermediate-risk PE in Europe, following successful APEX-AV study in the U.S. The trial aims to assess safety and efficacy, with primary endpoints focusing on RV/LV ratio reduction and Major Adverse Events incidence.